1Assistance Professor of Department of General Medicine, Jawaharlal Nehru Medical College, Belgaum, Karnataka
2Professor, Departments of Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
3Professor, Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
4Professor, Department of Cardiology, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
5Senior Lecturer, Department of Physiology, USM-KLE International Medical College
Online published on 11 February, 2016.
Chronic obstructive pulmonary disease (COPD) has become an important non-communicable disease worldwide with a rising global incidence. It is a major cause of morbidity and mortality globally. Co-morbid conditions usually have significant impact on health status, healthcare utilization, all-cause hospital admissions and mortality in COPD patients. Metabolic syndrome (MetS) is a common co-morbidity in COPD and is a risk factor for cardiovascular disease (CVD). This case control study was designed to assess the association of metabolic syndrome with COPD.
It was a case control blinded observational study. We evaluated 266 patients; 142 consecutive COPD patients and 124 age and sex-matched controls without COPD and cardiovascular disease from the medicine and pulmonary medicine outpatient department.
Prevalence of MetS was significantly higher amongst patients of COPD compared to controls 69.7% vs. 30.6% and odd ratio of 5.2 (95% C.I. of 3.0 to 8.7, p< 0.0001). Frequency of MetS according to severity of COPD were 72.7%, 76.5%, 63.6%, and 67.7% in GOLD stages I, II, III, and IV respectively.
The frequency of MetS high in COPD patients and COPD is an independent predictor of MetS. Screening for MetS should be a part of routine evaluation of people with COPD.
Metabolic syndrome, COPD, cardio vascular diseases
